A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group protocol 30867.
Fosså
S D
SD
Norwegian Radium Hospital, Oslo, Norway.
Splinter
T
T
Roozendaal
K J
KJ
Veenhof
K H
KH
Pavone-Macaluso
M
M
Calciati
A
A
de Pauw
M
M
Sylvester
R
R
D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D015251:Epirubicin